POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.
steven
My understanding is that the second yearlong phase III study of tesamorelin has been completed (I was in the first). I've sent repeated emails and letters to Theratechnologies with no reponse . . . you'd think that I'm at least minimally responsible for the 23 mil. going intro their pockets. clinicaltrial.gov doesn't show any recruitment.
November 5, 2008